SPARC

SPARC has undertaken a significant strategic reset over the last 24 months following two major clinical data readouts (PROSEEK Phase 2 and Vibozilimod Phase 2) that did not meet expectations. The company has narrowed its therapeutic focus to oncology and immunology, prioritizing two promising programs: MUC1 ADC (SBO-154) for solid tumors and a topical intervention (SCD-153) for Alopecia Areata. This shift aims to reduce clinical risk and optimize resource allocation.

SCD-153, a novel topical itaconate analogue, is currently in a Phase 1B clinical trial for alopecia areata. Enrollment in all cohorts is targeted for completion by Q3 2026, with an interim readout expected in Q4 2026. The study has completed enrollment for cohort 1 (15 patients) with no safety concerns, and cohort 2 is now enrolling with an optimized foam formulation. SPARC plans to initiate a global Phase 2 clinical study in Q2 2027. The company is also exploring SCD-153 for vitiligo, based on shared immune pathogenesis and promising in-vitro data showing inhibition of key chemokines.

SBO-154, an anti-MUC1 antibody drug conjugate with MMAE payload, is undergoing a Phase 1 dose escalation study in solid tumors across the US, Australia, and India. The first two dose levels have been completed without unexpected safety findings, and the third cohort is now enrolling. Management expects to complete dosing to the highest dose cohort (2.4 mg/kg) and identify the maximum tolerated dose (MTD) by Q3 2026. An early clinical proof of concept is anticipated by H2 2027, with expansion cohorts planned for ER-positive breast cancer, lung adenocarcinoma, and ovarian cancer.

SPARC is advancing SCO-155, a small-molecule drug conjugate targeting PSMA, through a NewCo called Tiller Therapeutics, formed with UCSF collaborators. Tiller has obtained exclusive global rights, with SPARC eligible for significant equity. The pre-IND consultation with FDA Oncology Division is complete, and Tiller is in the process of raising external seed capital for early-stage clinical funding. This NewCo structure is seen as a promising model for advancing late preclinical programs into the clinic and potentially for other late-stage assets like vodobatinib.

The path for vodobatinib in CML remains challenging due to a changing market landscape with new TKIs and limited licensing interest from large pharmaceutical companies. SPARC is considering alternative structures with partners and investors for its continued development. Separately, SPARC expects to receive a Pediatric Rare Diseases Voucher (PRV) by the end of January 2026, following a district court ruling in its favor, which could provide significant encashment, potentially exceeding $100 million.

SPARC has aggressively optimized its cost structure, achieving approximately $10 million in annual fixed cost savings. The company's headcount is projected to reduce from over 400 in FY24 to around 250 in FY27, with a significant reduction in US footprint and lab centers. Operational spend is projected to decrease from $31 million in FY25 to $29 million in FY26. However, SPARC acknowledges a need for significant additional resources beyond its cumulative $45 million-plus promoter-backed debt (as of Q2 FY26) and is finalizing a funding plan to extend its cash window to FY28, aiming to complete this process in H1 2026.